First data collection on the use of prophylactic migraine treatments including the monoclonal antibody Erenumab focused on the patient's personal experience (PERISCOPE)

Charly Gaul[1], Heike Israel-Willner[2], Katrin Schuh[3], Mirja Koch[3]

[1]Migraine and Headache Clinic, Koenigstein am Taunus, Germany,
[2]NFZB, Specialized Center of Neurology Berlin, Berlin, Germany
[3]Clinical Research Neuroscience, Novartis Pharma GmbH, Nuremberg, Germany

BACKGROUND

- Erenumab, the only approved fully human CGRP-receptor antibody, has been available in Germany since November 2018. So far only limited real world evidence (RWE) data are available
- Up until now, reduction of monthly migraine days (MMD) has served as a gold standard in evaluating therapeutic success of prophylactic migraine treatment. From the patient´s perspective however, other factors can have a high impact on their contentment with the achieved therapy outcome
- Thus evaluating benefit from the patients' view in real-world is of utmost importance in understanding the efficacy of a therapy beyond the endpoints of clinical trials

OBJECTIVE

- Periscope collected real-world-evidence data directly from migraine patients to characterize the impact of erenumab on their disease characteristics

METHODS

- From July to December 2019 an online survey targeting patients with migraine was conducted in Germany
- Patients were asked about their migraine history and their experience with pharmacological and non-pharmacological prophylactic therapies for migraine
- Patients receiving erenumab treatment for at least 3 months were specifically surveyed about the treatment outcome and effect on daily life

DISCLOSURE

Heike Israel-Willner received honoraria for consulting and lectures within the past 3 years from Allergan Pharma, Novartis Pharma, Desitin Arzneimittel and Teva. She does not hold any stocks of pharmaceutical companies or medical device companies.

Charly Gaul has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan Pharma, Ratiopharm, Boehringer Ingelheim Pharma, Lilly, Novartis Pharma, Desitin Arzneimittel, Cerbotec, Bayer vital, Hormosan Pharma, electroCore, Reckitt Benckiser, and Teva.

Mirja Koch and Katrin Schuh are employees at Novartis Pharma GmbH.

This study was funded by Novartis Pharma GmbH, Nürnberg, Germany.

RESULTS

- 29.042 migraine patients completed the survey, 155 received erenumab with a mean treatment duration of 6 months (129 were treated for more than 3 months)

Figure 1. Disease duration of migraine patients



- Migraine patients suffer from a disease duration for on average 19 years (n=28654)

Figure 2. Prior and current prophylactic treatments of migraine patients



- 0.74% of migraine patients are treated currently with monoclonal antibodies (n=153)

Figure 3. Prophylactic treatment in the cohort of patients



- 68% of all patients do not receive prophylactic treatment at the moment (n=19334)



- 38% of migraine patients use a non-pharmacologic prophylactic therapy (n=28,654)

Figure 4. Onset of erenumab effects on key migraine specific parameters



- On average, monthly migraine days reduced from 15.4 days before treatment to 7.9 days after three months of erenumab therapy (n=115)



- 95% of patients who respond after the first injection lost less days due to migraine symptoms

Figure 5. Effect of erenumab treatment on migraine-related symptoms



- Patients reported improvement in their most bothering symptoms following erenumab treatment (n=78)

Figure 6. Effect of erenumab treatment on migraine factors



- 70% of non-responder and 62% of responder* show an improvement in pain intensity (n=39)

Figure 6. Distribution by specialty of physicians prescribing erenumab



- In 78% of the erenumab patients, neurologists were the prescribing physicians (n=91)

CONCLUSION

- PERISCOPE provides us with first **real-world evidence data** for erenumab in Germany **from the patients'perspective**
- After three months of therapy, erenumab had a meaningful impact on MMD
- Erenumab mitigates most botherisome migraine-related symptoms
- Also patients considered as non-responders reported benefits from erenumab treatment
- Overall, the analysis shows that in real-world, erenumab patients experience and report benefits in various key migraine parameters